front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |review |
As grim as the future may look, there is some good news to
report regarding type 2 diabetes.
NIH research
has shown that type 2 diabetes can be delayed or prevented.
This figure depicts disease development in the
different racial and ethnic groups in the landmark Diabetes
Prevention Program (DPP) clinical trial. The DPP compared
three approaches -- lifestyle modification, treatment with
metformin, and standard medical advice -- in 3,234
overweight people at high risk of developing diabetes.
Patients who received standard medical advice and a sugar pill
(placebo) developed diabetes at the highest
rate (red bars).
Patients in the metformin group also developed diabetes, but
the overall rate was about 31 percent less than in the
placebo group (yellow
bars). Finally, the
lifestyle intervention group, the individuals who lowered
their caloric intake and walked about 30 minutes per day 5
times a week, showed the most dramatic improvement, with an
overall 58 percent decrease of diabetes cases compared to
placebo (blue bars). These improvements were seen across all
racial and ethnic groups, and in participants of all ages.
This study provides hope to all those prone to develop type 2
diabetes because it demonstrates that small
changes in lifestyle could delay or prevent this disease.
The NIDDK is currently following DPP participants to explore
the
durability of the interventions in preventing or delaying
type 2 diabetes and cardiovascular disease.
We are also vigorously disseminating the prevention
message of the DPP, with the hope that more individuals will
also benefit from these lessons learned.
|